Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down to $17.04

Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating)’s share price gapped down before the market opened on Friday . The stock had previously closed at $17.04, but opened at $16.68. Collegium Pharmaceutical shares last traded at $17.13, with a volume of 234 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright downgraded shares of Collegium Pharmaceutical to a “neutral” rating in a research report on Monday, August 15th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.25.

Collegium Pharmaceutical Trading Up 1.8 %

The company has a market cap of $591.81 million, a P/E ratio of -16.51, a P/E/G ratio of 0.20 and a beta of 0.86. The company has a debt-to-equity ratio of 3.16, a current ratio of 0.99 and a quick ratio of 0.80. The stock’s 50-day moving average is $17.88 and its two-hundred day moving average is $17.59.

Collegium Pharmaceutical (NASDAQ:COLLGet Rating) last announced its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($1.19). Collegium Pharmaceutical had a negative net margin of 11.24% and a negative return on equity of 2.12%. The business had revenue of $123.55 million for the quarter, compared to analysts’ expectations of $122.63 million. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 4.21 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in Collegium Pharmaceutical by 1.5% during the first quarter. BlackRock Inc. now owns 5,717,305 shares of the specialty pharmaceutical company’s stock valued at $116,403,000 after buying an additional 85,645 shares during the last quarter. Vanguard Group Inc. increased its holdings in Collegium Pharmaceutical by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,306,529 shares of the specialty pharmaceutical company’s stock valued at $46,962,000 after buying an additional 19,112 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Collegium Pharmaceutical by 22.6% during the second quarter. Principal Financial Group Inc. now owns 1,738,291 shares of the specialty pharmaceutical company’s stock valued at $30,802,000 after buying an additional 320,778 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Collegium Pharmaceutical by 10.0% in the second quarter. Renaissance Technologies LLC now owns 1,396,818 shares of the specialty pharmaceutical company’s stock worth $24,752,000 after purchasing an additional 126,700 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Collegium Pharmaceutical by 6.3% in the second quarter. State Street Corp now owns 1,390,693 shares of the specialty pharmaceutical company’s stock worth $24,643,000 after purchasing an additional 82,526 shares in the last quarter.

Collegium Pharmaceutical Company Profile

(Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Recommended Stories

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.